Syros Pharmaceuticals Receivables

Syros Pharmaceuticals (SYRS) currently reports a receivables of $0 as of September 2024. That compares with $1.7M in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Syros Pharmaceuticals's receivables history and peer comparisons.

Syros Pharmaceuticals's receivables decreased from $1.7M to $0 — a 100.0% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Syros Pharmaceuticals reported $0 in receivables as of September 2024. That compares with $1.7M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Syros Pharmaceuticals, and consider following SYRS for alerts when major investors trade the stock.

Syros Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SYRS with unrelated industries.